higher rates of nausea, vomiting, and discontinuation without meaningful long-term Starting to see how this market will evolve
The interaction between retatrutide and other peptides depends entirely on the mechanisms involved
23 As such, the current study was important as it utilized a large cohort of commercially insured individuals to examine the impact of GLP-1RA medications on the incidence of common thoracic, gastrointestinal, gynecologic, and endocrine cancers
Trial dose range: 112mg, once weekly, subcutaneous Standard escalation: 2mg +2mg every 4 weeks 12mg (~20 weeks) Pharmacokinetics: half-life ~6 days
Phase 3 TRIUMPH trials are ongoing, with results expected throughout 2026
The small intestine responds to increased GLP-1 signaling by altering fluid secretion patterns, which can produce loose or watery stools in the adaptation period